News Releases

Date Title and Summary Additional Formats
June 22, 2020 Ayala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
– Completed upsized initial public offering raising a total of $59.1 million in gross proceeds – Current cash balance expected to fund operations into second half of 2022 – Fast Track Designation granted for lead candidate, AL101 for the treatment of R/M ACC; additional Phase 2 data expected in
June 1, 2020 Ayala Pharmaceuticals to Present at Upcoming Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., June 01, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
May 12, 2020 Ayala Pharmaceuticals Announces Closing of Initial Public Offering
REHOVOT, Israel & WILMINGTON, Del., May 12, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically
May 7, 2020 Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
REHOVOT, Israel and WILMINGTON, Del., May 07, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
March 3, 2020 Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation For AL101 For The Treatment Of Recurrent Or Metastatic Adenoid Cystic Carcinoma
REHOVOT, Israel & WILMINGTON, Del., March 2, 2020 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that the U.S.